VTRS Q3 2021 Earnings — Viatris Inc. Revenue & Financial Results | Market Cap Arena

VTRSViatris Inc.

$16B

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$4.5B+52.6% YoY

Gross Profit

$1.6B34.7% margin

Operating Income

$358M7.9% margin

Net Income

$312M6.9% margin

EPS (Diluted)

$0.26

QoQ Revenue Growth

-0.9%

Cash Flow

Operating Cash Flow

$1.1B

Free Cash Flow

$954M

Stock-Based Comp.

$25M

Balance Sheet

Total Assets

$56.1B

Total Liabilities

$34.9B

Stockholders' Equity

$21.1B

Cash & Equivalents

$757M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$4.5B	$3.0B	+52.6%
Gross Profit	$1.6B	$1.2B	+35.9%
Operating Income	$358M	$351M	+1.8%
Net Income	$312M	$186M	+67.7%

Revenue Segments

Brands

$2.8B62%

Generics

$1.4B31%

Complex GX and Biosimilars

$332M7%

Geographic Segments

Developed Markets Segment

$2.7B59%

Emerging Markets Segment

$793M18%

Greater China Segment

$567M13%

Japan, Australia and New Zealand Segment

$505M11%